One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...

Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer in treating high cholesterol, it said.

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial ...

Entrepreneur Cathy Tie, often called “Biotech Barbie” has launched a new startup, Origin Genomics, following the closure of her previous firm, Manhattan Genomics, earlier this year.Tie remains focused ...

Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing.